Want to see JP:7774 full AI Analyst Report?
7774 Stock Chart & Stats
¥575.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥575.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥448.00 - ¥893.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)51.90K
Market Cap
¥35.01B
Enterprise Value¥21.99K
Total Cash (Recent Filing)¥3.35B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.84
Shares Outstanding40,610,200
10 Day Avg. Volume45,190
30 Day Avg. Volume51,896
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.75
Price to Sales (P/S)11.09
P/FCF Ratio-43.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.9
Revenue Forecast (FY)¥5.05B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Minimal LeverageEffectively no debt and substantial equity (about ¥5.09B in 2026) materially reduce solvency risk and give the company financial flexibility. This durable strength provides runway to fund R&D, absorb operating variability, and pursue strategic options over the next 2–6 months.
Proven Cash Generation In Stronger PeriodsThe company has shown it can generate positive operating and free cash flow in better periods, indicating an operational model that can deliver cash when revenue conditions improve. This suggests management can potentially restore cash generation via cost control or revenue recovery rather than structural failure.
Specialized Regenerative-medicine Business ModelFocus on cell- and tissue-based therapies reflects a specialized, high-barrier business model with product complexity and regulatory entry hurdles. These structural characteristics can create durable competitive advantages, pricing power, and sticky customer relationships over multiple quarters to years.
Bears Say
Worsening Profitability And Large Net LossesProfitability deteriorated sharply, swinging from meaningful net income in 2024 to large losses in 2025–2026. Persistent losses erode retained equity, reduce reinvestment capacity, and impair the firm’s ability to demonstrate sustainable margins necessary for long-term commercial scaling.
Accelerating Cash Burn And Negative Free Cash FlowSubstantial negative operating and free cash flow in 2026 indicates accelerating cash burn versus prior years. This trend increases reliance on balance-sheet resources, heightens financing risk or dilution, and may force near-term cutbacks that weaken commercial progress and R&D timelines.
Top-line Volatility And Recent Revenue DeclinesRevenue volatility and back-to-back declines after 2024 undermine scale economies and make future margin recovery uncertain. Weakening sales trends limit predictability for capacity planning and investment, raising the risk that fixed costs will continue to pressure operating results over the medium term.
Japan Tissue Engineering Co., Ltd. News
7774 FAQ
What was Japan Tissue Engineering Co., Ltd.’s price range in the past 12 months?
Japan Tissue Engineering Co., Ltd. lowest stock price was ¥448.00 and its highest was ¥893.00 in the past 12 months.
What is Japan Tissue Engineering Co., Ltd.’s market cap?
Japan Tissue Engineering Co., Ltd.’s market cap is ¥35.01B.
When is Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date?
Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date is Nov 04, 2026 which is in 84 days.
How were Japan Tissue Engineering Co., Ltd.’s earnings last quarter?
Japan Tissue Engineering Co., Ltd. released its earnings results on Jul 30, 2026. The company reported ¥1.29 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Japan Tissue Engineering Co., Ltd. overvalued?
According to Wall Street analysts Japan Tissue Engineering Co., Ltd.’s price is currently Overvalued.
Does Japan Tissue Engineering Co., Ltd. pay dividends?
Japan Tissue Engineering Co., Ltd. does not currently pay dividends.
What is Japan Tissue Engineering Co., Ltd.’s EPS estimate?
Japan Tissue Engineering Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Tissue Engineering Co., Ltd. have?
Japan Tissue Engineering Co., Ltd. has 40,610,200 shares outstanding.
What happened to Japan Tissue Engineering Co., Ltd.’s price movement after its last earnings report?
Japan Tissue Engineering Co., Ltd. reported an EPS of ¥1.29 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Japan Tissue Engineering Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7774
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.